

09.00-12.00 h INoPSU Business Meeting

Sponsors: Swiss Society of Paediatrics (SSP) and Federal Office of Public Health (FOPH)

12.00-13.30 h SPSU and INoPSU Business Lunch

INoPSU Scientific Meeting Montreux Friday 2nd September 2011

Hour	Last Name	First Name	Country	Title
Chairs: K Posfay Barbe/?				
13.30	Rudin	Christoph	CH	The Swiss Paediatric Surveillance Unit SPSU: Highlights of 15 years of operation
13.45	Sabbe	Martine	BPSU	The Belgian Paediatric Surveillance Unit "PediSurv"
14.00	Zenner	Dominik	UK	The BPSU - 25 years of informing vaccination policy?
14.15	Zurinsky	Yvonne	AUS	The Importation of engaging with patient support groups: education, research and influencing national policy on rare disease
14.30	Grenier	Danielle	CAN	Paediatric Emergency Department Surveillance of Injuries Associated with Baby Products, Canadian Hospitals Injury Reporting and Prevention Programm (CHIRPP), 1990-2008, children under six years of age and a 2010 CPSP survey
14.45	van der Lely	Nico	NL	Alcohol coma admissions in the Netherlands
15.00-15.15	Pause			
Chairs: G. Simonetti/?				
15.15	Schweizer	Joachim	NL	The 3 rd national survey on childhood celiac disease in the Netherlands: still changing epidemiology and clinical presentation.
15.30	Lips	Ulrich	CH	Shaken baby syndrome in Switzerland: results of a prospective follow-up study, 2002-2007
15.45	von Vigier	Rodo	CH	Haemolytic uraemic syndrome in Switzerland: Twelve years prospective surveillance
16.00	Winstone	AnneMarie	UK	Guillain-Barré/Fisher syndrome surveillance in the UK; is there a temporal association with influenza infection or vaccination
16.15	Zurinsky	Yvonne	AUS	Vitamin D deficiency rickets in Australia: need for screening and early treatment in high risk groups
16.30	Grenier	Danielle	CAN	Can active surveillance improve reporting of serious and life-threatening adverse drug reactions? - The CPSP experience
16.45	Roth-Kleiner	Matthias	CH	Severe Hyperbilirubinaemia of the newborn: a problem in Switzerland?
17.00	Zenner	Dominik	UK	A lasting legacy? A BPSU study case review to evaluate public health impact
17.15-17.45	Panel discussion:			